Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SX-682 · 1 trial · 1 indication
The biological active and tolerable combination doses are those that satisfy observed DLT rate\<33% and demonstrate reduction in myeloid derived suppressor cells (MDSCs).
Response rate on the basis of Prostate Cancer Working Group 3 (PCWG3), and/or Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
| Arm | Type | Description |
|---|---|---|
| Phase I: Dose Escalation | EXPERIMENTAL | Phase I will identify a biologically active and tolerable (safe) dose range of SX-682 in combination with Apalutamide in patients with metastatic castrate-resistant prostate cancer (mCRPC). |
| Phase II: Dose Expansion | EXPERIMENTAL | Phase I will investigate the anti-tumour activity of tolerable doses of SX-682 in combination with Apalutamide in patients with metastatic castrate-resistant prostate cancer (mCRPC). Patients will be treated at dose levels deemed to be tolerable and biologically active, based on safety and efficacy data from Dose Escalation. |
| Name | Type | Description |
|---|---|---|
| SX-682 | DRUG | SX-682 is supplied as 100mg film coated tablets. |
| Apalutamide | DRUG | Apalutamide is supplied as 60mg film coated tablets. |
Inclusion Criteria: 1. Written informed consent and be capable of cooperating with treatment. 2. Age ≥ 18 years. 3. Histologically or biochemically confirmed adenocarcinoma of the prostate and with tumour tissue accessible for research analysis for this trial. Patients who have no histological diag...
SX-682 is an investigational small molecule being studied for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SX-682 is a small molecule that targets the CXCR1 and CXCR2 chemokine receptors. By inhibiting these receptors, it may modulate the tumor microenvironment and enhance anti-tumor immune responses in metastatic castrate-resistant prostate cancer.
SX-682 is being developed by United Therapeutics Corporation, a publicly traded company listed on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
SX-682 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing trial is recruiting patients with metastatic castrate-resistant prostate cancer.
SX-682 is being evaluated in a Phase 1 clinical trial with the identifier NCT07002320. This study is investigating SX-682 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The trial is currently recruiting participants in Switzerland and the United Kingdom.
No, SX-682 is not the same as apalutamide. SX-682 is an investigational small molecule that targets CXCR1 and CXCR2, while apalutamide is an approved androgen receptor inhibitor. In the ongoing clinical trial, SX-682 is being studied in combination with apalutamide.